Cite
HARVARD Citation
Vano, Y. et al. (2022). Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet oncology. 23 (5), pp. 612-624. [Online].